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In general, 80% of advanced germ cell tumors (GCTs) with metastasis can be cured, since clinical
treatment guidelines for testicular cancer has been established after the International Germ Cell Cancer
Collaborative Group announcement in 1997. Of those with advanced GCTs, 20-30% of the cases are
defined as ‘difficult-to-treat’ GCTs. In particular, inadequate induction chemotherapy might result in
“refractory” or “resistant” GCTs. In such cases, salvage chemotherapy will be required. Long-term
survival can be guaranteed in 30% of the cases treated by conventional VIP (etoposide, ifosfamide, cisplatin)
or VeIP (vinblastine, ifosfamide, cisplatin) therapy. Previously, high-dose chemotherapy (HDCT) was
attemped to gain better results as induction therapy, but has not been shown to be superior to conventional
chemotherapy. Furthermore a randomized control trial failed to show the superiority of HDCT as an
induction therapy. Therefore, new drugs such as paclitaxel, gemcitabine and irinotecan have been used as
salvage chemotherapy. Especially, TIP (paclitaxel, ifosfamide, cisplatin) therapy has become a new
treatment option as first salvage chemotherapy in patients with favorable features such as testis primary and
first relapse after complete remission. Regarding gemcitabine or irinotecan, some regimens have been
reported in combination with oxaliplatin or paclitaxel. These studies were performed using multi-regimen
chemotherapy, so the efficacy was limited. According to the Japanese guidelines for testicular cancer TIP
therapy is recommendation grade B and gemcitabone-containing therapy is grade C. Currently, it is very
difficult to conduct a randomized control trial on a large scale in a salvage setting. It is necessary to
accumulate a number of cases with advanced GCTs in high-volume centers.
(Hinyokika Kiyo 58 : 721-725, 2012)































































Fig. 3. 進行性精巣腫瘍 salvage 化学療法∼京都府立医大方針∼
Table 1. 従来の救済化学療法




Farhat3) VIP/VeIP 54 2nd line 44 30
McCaffrey4) VIP/VeIP 56 2nd line 36 34
Loehrer5) VeIP 135 2nd line 50 24
化学療法開始時おける IGCC 分類，すなわち IGCCC
at salvage が報告された18)．導入化学療法時の IGCCC
の概念を救済化学療法にも応用した内容となってい
る．1,435例の予後予測因子を解析し，スコア化する
ことで 5群に分類している (Table 3，4）． 5群間で無
再発生存率に有意差を認めた．
当院での救済化学療法
当院での救済化学療法の方針を Fig. 3 に示す．導入
化学療法後 2nd line としては，TIN（パクリタキセ
Table 2. 新規抗がん剤による救済化学療法
報告者 レジメン 症例数 施行時期 奏効率（％) CR（％) NED（％)
Motzer10) TIP 30 2nd line，CR 後の first relapse 80 77 73
Mead11) TIP 43 2nd line 60 19 2y-OS : 65
Kollmannsberger12) GO 35 2nd line 以降 46 9 11
Nicolai13) TPG 22 3rd line 以降 36.4 0 18.2
Shiraishi14) TGN 15 3rd line 以降 47 0 ―
Miki15) IrN/IrP 18 2nd line 以降 50 11 50
Pectasides16) IrO 18 3rd line 40 17 17
Shamash17) IPO 28 3rd line 71 18 29
ル，イホスファミド，ネダプラチン）療法またはイリ
ノテカン/ネダプラチン療法を行っている．現在では
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Table 3. IGCCCG-2 (Lorch-Beyer) score construction
Points
Variables -1 0 1 2 3
Histology Seminoma Non-seminoma
Primary site Gonadal Retroperitoneal Mediastinal
Response CR/PRm- PRm＋/SD PD
PFI ＞3 months 3 months
AFP salvage Normal ＜1,000 1,000
HCG salvage ＜1,000 1,000
LBB No Yes
AFP＝alpha-fetoprotein ; hCG＝human chorionic gonadotropin ; IGCCCG＝International Germ
Cell Cancer Collaborative Group ; LBB＝ liver, bone, brain metastasis ; PFI＝ platimum-free
interval.
Table 4. PFS and OS estimates for all patients
according to IGCCCG-2 prognostic score
N ％ HR 2y-PFS 3y-OS
Score (N＝1,435)
Very low (−1) 76 5.30 1 75.1 77.0
Low (0) 257 17.9 2.07 52.6 69.0
Intermediate (1) 646 45.0 2.88 42.8 57.3
High (2) 351 24.5 4.81 26.4 31.7
Very high (3) 105 7.3 8.95 11.5 14.7
Missing 159
IGCCCG ＝ International Germ Cell Cancer Collaborative
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